DKK-3 Protein, Human (HEK293, His)

Customer Review

Based on 1 Customer Validation

DKK-3 protein antagonizes canonical Wnt signaling by blocking LRP5/6-Wnt interactions and forming a ternary complex with KREMEN, thereby promoting LRP5/6 internalization.In vertebrate development, DKK-3, together with other DKKs, critically inhibits Wnt-regulated processes such as axial patterning, limb development, somitogenesis, and eye formation.DKK-3 Protein, Human (HEK293, His) is the recombinant human-derived DKK-3 protein, expressed by HEK293 , with C-6*His labeled tag.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: HEK293
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • Help & FAQs

Biological Activity

Description

DKK-3 protein antagonizes canonical Wnt signaling by blocking LRP5/6-Wnt interactions and forming a ternary complex with KREMEN, thereby promoting LRP5/6 internalization.In vertebrate development, DKK-3, together with other DKKs, critically inhibits Wnt-regulated processes such as axial patterning, limb development, somitogenesis, and eye formation.DKK-3 Protein, Human (HEK293, His) is the recombinant human-derived DKK-3 protein, expressed by HEK293 , with C-6*His labeled tag.

Background

The DKK-3 protein functions as an antagonist of canonical Wnt signaling by impeding the interaction between LRP5/6 and Wnt and forming a ternary complex with the transmembrane protein KREMEN, facilitating the internalization of LRP5/6. Within vertebrate development, DKKs, including DKK-3, play a crucial role by locally inhibiting Wnt-regulated processes such as antero-posterior axial patterning, limb development, somitogenesis, and eye formation. In the adult, DKKs are implicated in diverse physiological and pathological conditions, encompassing bone formation, bone disease, cancer, and Alzheimer's disease (By similarity). Notably, DKK-3's interaction with LRP5 and LRP6 highlights its regulatory involvement in inhibiting Wnt signaling and its potential impact on various cellular processes.

Verified Bioactivity

Measured by its ability to inhibit proliferation of HeLa human cervical epithelial carcinoma cells. The ED50 for this effect is 6.403 μg/mL, corresponding to a specific activity is 1.561×10^2 units/mg.

MCE Validation Data

  • Purity - SDS-PAGE

    Purity - SDS-PAGE

    ≥ 95%, as determined by reducing SDS-PAGE.

  • Bioactivity - Cell-Based Assay

    Bioactivity - Cell-Based Assay

    Measured by its ability to inhibit proliferation of HeLa human cervical epithelial carcinoma cells. The ED50 for this effect is 6.403 μg/mL, corresponding to a specific activity is 1.561×10^2 units/mg.

Technical Parameters

  • Species Human
  • Source HEK293
  • Tag C-6*His
  • Accession
  • Gene ID
  • Molecular Construction
    • N-term
    • DKK-3 (A22-I350)
      Accession # AAF02676.1
    • 6*His
    • C-term
  • Protein Length

    Full Length of Mature Protein

  • Synonyms

    DKK3; HDkk-3; Dickkopf Wnt Signaling Pathway Inhibitor 3; Dkk-3; REIC; Dickkopf WNT Signaling Pathway Inhibitor 3; Dickkopf-Related Protein 3; Dickkopf (Xenopus Laevis) Homolog 3; CRRL; Dickkopf 3 Homolog (Xenopus Laevis); RIG; Dickkopf 3 Homolog; Cardiom

  • AA Sequence

    APAPTATSAPVKPGPALSYPQEEATLNEMFREVEELMEDTQHKLRSAVEEMEAEEAAAKASSEVNLANLPPSYHNETNTDTKVGNNTIHVHREIHKITNNQTGQMVFSETVITSVGDEEGRRSHECIIDEDCGPSMYCQFASFQYTCQPCRGQRMLCTRDSECCGDQLCVWGHCTKMATRGSNGTICDNQRDCQPGLCCAFQRGLLFPVCTPLPVEGELCHDPASRLLDLITWELEPDGALDRCPCASGLLCQPHSHSLVYVCKPTFVGSRDQDGEILLPREVPDEYEVGSFMEEVRQELEDLERSLTEEMALGEPAAAAAALLGGEEI

  • Molecular Weight

    Approximately 73 kDa, based on SDS-PAGE under reducing conditions.

  • Glycosylation

    Yes

  • Purity

    ≥ 95%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder

Formulation

Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.2.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00